Search Results - "Schellong, Sebastian M."

Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial by Beyer-Westendorf, Jan, Prof, Schellong, Sebastian M, Prof, Gerlach, Horst, MD, Rabe, Eberhard, Prof, Weitz, Jeffrey I, Prof, Jersemann, Katja, PhD, Sahin, Kurtulus, PhD, Bauersachs, Rupert, Prof

“…Summary Background Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism. Rivaroxaban, an oral factor Xa inhibitor, might…”
Get full text

Diagnosis of deep-vein thrombosis: adherence to guidelines and outcomes in real-world health care by Schellong, Sebastian M, Gerlach, Horst, Hach-Wunderle, Viola, Rabe, Eberhard, Riess, Hanno, Carnarius, Heike, Eberle, Sonja, Bauersachs, Rupert

“…Current guidelines recommend optimised algorithms for diagnosis of suspected deep-vein thrombosis (DVT). There is little data to determine to what extent…”
Get more information

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial by Koehler, Friedrich, Koehler, Kerstin, Deckwart, Oliver, Prescher, Sandra, Wegscheider, Karl, Kirwan, Bridget-Anne, Winkler, Sebastian, Vettorazzi, Eik, Bruch, Leonhard, Oeff, Michael, Zugck, Christian, Doerr, Gesine, Naegele, Herbert, Störk, Stefan, Butter, Christian, Sechtem, Udo, Angermann, Christiane, Gola, Guntram, Prondzinsky, Roland, Edelmann, Frank, Spethmann, Sebastian, Schellong, Sebastian M, Schulze, P Christian, Bauersachs, Johann, Wellge, Brunhilde, Schoebel, Christoph, Tajsic, Milos, Dreger, Henryk, Anker, Stefan D, Stangl, Karl

“…Remote patient management in patients with heart failure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt…”
Get full text

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism by BÜLLER, Harry R, DECOUSUS, Hervé, MINGGAO SHI, VERHAMME, Peter, WELLS, Phil, GROSSO, Michael A, MERCURI, Michele, MIDDELDORP, Saskia, PRINS, Martin H, RASKOB, Gary E, SCHELLONG, Sebastian M, SCHWOCHO, Lee, SEGERS, Annelise

“…The anticoagulant edoxaban, an oral inhibitor of activated factor X, does not require monitoring. As initial treatment for acute venous thromboembolism,…”
Get full text

Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY by Haas, Sylvia, Schellong, Sebastian M, Tebbe, Ulrich, Gerlach, Horst-Eberhard, Bauersachs, Rupert, Melzer, Nima, Abletshauser, Claudia, Sieder, Christian, Bramlage, Peter, Riess, Hanno

“…Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2)…”
Get full text

Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: A subgroup analysis of the randomized, controlled CERTIFY study by Tebbe, Ulrich, MD, Schellong, Sebastian M., MD, Haas, Sylvia, MD, Gerlach, Horst Eberhard, MD, Abletshauser, Claudia, PhD, Sieder, Christian, MSc, Bramlage, Peter, MD, Riess, Hanno, MD

“…Background Despite the elevated risk for developing venous thromboembolic events in patients with heart failure, there are no randomized, double-blind,…”
Get full text

Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry by Schellong, Sebastian M, Goldhaber, Samuel Z, Weitz, Jeffrey I, Ageno, Walter, Bounameaux, Henri, Turpie, Alexander G G, Angchaisuksiri, Pantep, Haas, Sylvia, Goto, Shinya, Zaghdoun, Audrey, Farjat, Alfredo, Nielsen, Joern Dalsgaard, Kayani, Gloria, Mantovani, Lorenzo G, Prandoni, Paolo, Kakkar, Ajay K

“…Isolated distal deep vein thrombosis (IDDVT) represents up to half of all lower limb DVT. This study investigated treatment patterns and outcomes in 2,145…”
Get more information

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial by Hull, Russell D, Schellong, Sebastian M, Tapson, Victor F, Monreal, Manuel, Samama, Meyer-Michel, Nicol, Philippe, Vicaut, Eric, Turpie, Alexander G G, Yusen, Roger D

“…Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients. To evaluate the efficacy…”
Get full text

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry by Haas, Sylvia, Ten Cate, Hugo, Accetta, Gabriele, Angchaisuksiri, Pantep, Bassand, Jean-Pierre, Camm, A John, Corbalan, Ramon, Darius, Harald, Fitzmaurice, David A, Goldhaber, Samuel Z, Goto, Shinya, Jacobson, Barry, Kayani, Gloria, Mantovani, Lorenzo G, Misselwitz, Frank, Pieper, Karen, Schellong, Sebastian M, Stepinska, Janina, Turpie, Alexander G G, van Eickels, Martin, Kakkar, Ajay K

“…Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of…”
Get full text

Low risk is not enough: the dilemma of calf vein thrombosis by Schellong, Sebastian M

Get full text

Dabigatran for the treatment of venous thromboembolism by Schellong, Sebastian M

“…Venous thromboembolism (VTE) is a major cause of morbidity and mortality, and individuals with a first VTE are at risk of recurrent VTE. VTE treatment is…”
Get more information

Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis by Schwarz, Thomas, Schmidt, Benjamin, Schmidt, Barbara, Schellong, Sebastian M

“…The interobserver variability of compression ultrasound of proximal and distal veins in clinically suspected deep vein thrombosis was assessed. One hundred one…”
Get more information

International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs by Parry, Blair Alden, Chang, Anna Marie, Schellong, Sebastian M., House, Stacey L., Fermann, Gregory J., Deadmon, Erin K., Giordano, Nicholas J., Chang, Yuchiao, Cohen, Jason, Robak, Nancy, Singer, Adam J., Mulrow, Mary, Reibling, Ellen T., Francis, Samuel, Griffin, S. Michelle, Prochaska, Jürgen H., Davis, Barbara, McNelis, Patricia, Delgado, Joao, Kümpers, Philipp, Werner, Nikos, Gentile, Nina T., Zeserson, Eli, Wild, Philipp S., Limkakeng, Alexander T., Walters, Elizabeth Lea, LoVecchio, Frank, Theodoro, Daniel, Hollander, Judd E., Kabrhel, Christopher

“…We sought to determine the test characteristics of an automated INNOVANCE D-dimer assay for the exclusion of pulmonary embolism (PE) and deep venous thrombosis…”
Get full text

Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients by Lawall, Holger, Oberacker, Ralph, Zemmrich, Claudia, Bramlage, Peter, Diehm, Curt, Schellong, Sebastian M

“…Data on prevalence rates of venous thromboembolism (VTE) in different patient populations are scarce. Most studies on this topic focus on older patients or…”
Get full text

Venous ultrasonography in symptomatic and asymptomatic patients: an updated review by Schellong, Sebastian M

“…PURPOSE OF REVIEWVenous ultrasound is a major tool in both routine clinical care and clinical research. Since the last review, major attempts have been made to…”
Get full text

Continuation of venous thromboembolism prophylaxis after hospital discharge into the outpatient setting: the ACCEPT study by Schellong, Sebastian M., Kaiser, Jürgen, Bramlage, Peter

“…Transition from the hospital into the outpatient setting is a critical event for the appropriate provision of VTE prophylaxis. Data for this transition for the…”
Get full text

Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis by Bauersachs, Rupert M, Riess, Hanno, Hach-Wunderle, Viola, Gerlach, Horst, Carnarius, Heike, Eberle, Sonja, Rabe, Eberhard, Schellong, Sebastian M

“…It is uncertain whether gender influences the clinical presentation of deep-vein thrombosis (DVT) and the discriminative value of the Wells diagnostic pretest…”
Get more information

Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study by TURPIE, Alexander G. G, HULL, Russell D, SCHELLONG, Sebastian M, TAPSON, Victor F, MONREAL, Manuel, SAMAMA, Meyer-Michel, MIN CHEN, YUSEN, Roger D

“…The optimal duration of venous thromboembolism prophylaxis in acute stroke patients is unknown. This subanalysis of the Extended Prophylaxis for Venous…”
Get full text

Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial by Yusen, Roger D, Hull, Russell D, Schellong, Sebastian M, Tapson, Victor F, Monreal, Manuel, Samama, Meyer-Michel, Chen, Min, Deslandes, Bruno, Turpie, Alexander G G

“…The EXCLAIM study enrolled hospitalised acutely ill medical patients with age >40 years and recently-reduced mobility into a trial of extended-duration…”
Get more information

Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication - results of a randomised clinical trial by Schellong, Sebastian M, von Bilderling, Peter, Gruss, Jörg D, Lawall, Holger, Grieger, Frank, Ney, Ulrich, Bramlage, Peter, Diehm, Curt, Bentz, Jürgen

Get more information